Related Experiment Video
Updated: Jul 20, 2026
09:41
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
Published on: July 19, 2019
[Pathology and definition of multiple sclerosis]
1Department of Neuroscience, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.
La Revue Du Praticien
|September 5, 2006
Summary
Multiple sclerosis (MS) is characterized by inflammatory demyelinating lesions in the central nervous system (CNS). Understanding the dynamics of these lesions and their relationship to progressive degeneration is key to MS research.
Area of Science:
- Neurology
- Immunology
- Pathology
Context:
- Multiple sclerosis (MS) diagnosis relies on identifying inflammatory demyelinating lesions (plaques) within the central nervous system (CNS).
- These lesions exhibit dynamic behavior, with acute formation, regression, and new lesion development throughout the disease course.
- The characteristic 'dissemination in space and time' reflects ongoing inflammatory activity.
Purpose:
- To explore the pathological hallmarks of multiple sclerosis (MS).
- To differentiate between the focal lesions prominent in the relapsing-remitting phase and the diffuse degeneration seen in progressive MS.
- To address controversies regarding distinct immunohistopathological patterns versus disease stages, and the nosological classification of MS variants.
Summary:
- MS pathology involves inflammatory demyelinating foci in the CNS white matter, with continuous dynamics of lesion formation and regression.
- While focal lesions dominate early MS, progressive phases are marked by atrophy and axonal loss, leading to irreversible disability.
- Ongoing debates question whether observed patterns represent distinct disease subtypes or different stages of a single entity, and the primary driver of myelin destruction (autoimmunity vs. oligodendrocyte apoptosis).
Impact:
- Clarifying MS pathological heterogeneity can refine diagnostic criteria and therapeutic strategies.
- Understanding the transition from inflammatory lesions to progressive degeneration is crucial for developing treatments to halt irreversible neurological decline.
- Resolving controversies in MS classification may lead to more personalized treatment approaches.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:25Introduction to Language of Pathophysiology l
Pathophysiology investigates how biological mechanisms—typically starting at the cellular level—disrupt normal bodily functions. It bridges anatomy and physiology to explain the progression of disease. With this foundation, it is important to understand the following key terms used to describe disease processes: Diagnosis:The process of identifying a disease using clinical evaluation, including signs (objective evidence like rashes), symptoms (subjective experiences like pain), laboratory test...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:26Encephalitis ll: Pathophysiology
Encephalitis is inflammation of the brain parenchyma caused by direct viral invasion or immune-mediated mechanisms triggered by infections or tumors. Both processes lead to neuronal injury, disrupted neurotransmission, and diverse neurological symptoms, often with overlapping clinical and pathological features.Autoimmune EncephalitisIn autoimmune encephalitis, antibodies target neuronal antigens on cell surfaces, synapses, or within neurons. A key example is anti-NMDAR encephalitis, which can...